(Corrects drug spelling in headline, second paragraph of story published June 8.)
Roche Holding AG (ROG)’s personalized drug treatment for a fast-growing type of breast cancer won approval from U.S. regulators.
Perjeta, chemically known as pertuzumab, is designed to work with the Basel, Switzerland-based company’s Herceptin and chemotherapy to attack breast cancer that has spread in patients who have a certain gene mutation. The Food and Drug Administration today cleared Perjeta for consumer use, Roche’s Genentech unit said in a statement.
To contact the reporter on this story: Anna Edney in Washington at email@example.com.
To contact the editor responsible for this story: Reg Gale at firstname.lastname@example.org